What Is Mounjaro? Tirzepatide Explained

Mounjaro has become one of the most talked-about injectable medications in metabolic medicine.

But what exactly is Mounjaro, and how is it different from GLP-1 medications such as Wegovy?

The key difference starts with its active ingredient: tirzepatide.

Tirzepatide does not act on only one hormonal pathway. It activates both GIP and GLP-1 receptors, which is why it is often described as a dual GIP/GLP-1 receptor agonist.

Understanding these two pathways helps explain why tirzepatide can influence blood glucose, appetite, food intake and body weight.

What Is in Mounjaro?

The active ingredient in Mounjaro is tirzepatide.

It is administered as a once-weekly subcutaneous injection.

According to the U.S. prescribing information, tirzepatide selectively binds to and activates two receptors:

• GIP receptor
• GLP-1 receptor

Both GIP, or glucose-dependent insulinotropic polypeptide, and GLP-1, or glucagon-like peptide-1, are naturally occurring incretin hormones involved in the body's response to food.

This dual action is one of the main characteristics that distinguishes tirzepatide from medications that primarily target the GLP-1 receptor alone.

How Does Tirzepatide Work?

After we eat, the gastrointestinal system communicates with organs such as the pancreas and brain through multiple hormonal signals.

GIP and GLP-1 are part of this system.

Tirzepatide activates receptors for both hormones.

According to FDA prescribing information, tirzepatide can enhance insulin secretion and reduce glucagon levels in a glucose-dependent manner. It also lowers fasting and post-meal glucose concentrations and can decrease food intake.

In practical terms, tirzepatide may influence several processes at the same time:

Blood glucose regulation
Tirzepatide helps increase insulin secretion when blood glucose is elevated.

Glucagon regulation
It can reduce glucagon levels in a glucose-dependent manner, helping regulate glucose production.

Appetite and food intake
Activation of incretin pathways can influence appetite-related signaling, and clinical pharmacology data show that tirzepatide decreases food intake.

Body weight
Reduced energy intake, together with metabolic effects, can contribute to weight reduction in appropriate patients.

Why Is Mounjaro Different From Wegovy?

Mounjaro and Wegovy are sometimes grouped together because both involve incretin-related pathways and are administered by injection.

But they are not the same medication.

Mounjaro contains tirzepatide, which activates:

GIP + GLP-1 receptors

Wegovy contains semaglutide, which acts primarily as a:

GLP-1 receptor agonist

So Mounjaro is not simply another brand of semaglutide.

The molecules, receptor targets and approved indications are different.

That does not mean one medication is automatically appropriate for every patient. Treatment choice depends on the person's medical history, treatment goals, approved indication and clinical assessment.

Is Mounjaro Approved for Weight Loss?

This is where the answer becomes more complicated.

The approved use of Mounjaro depends on the country.

For example, in the United States, the FDA currently approves Mounjaro as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.

In the United States, tirzepatide used for chronic weight management is marketed separately under the brand Zepbound rather than Mounjaro.

In the European Union, however, the EMA authorization for Mounjaro itself includes weight management in adults with obesity, or overweight with at least one weight-related comorbidity, in addition to its type 2 diabetes indication.

This is why statements such as:

“Mounjaro is a weight-loss drug”

can be misleading without specifying the country.

Regulatory approvals, brand names and indications can differ between markets.

How Often Is Mounjaro Used?

Mounjaro is administered once weekly by subcutaneous injection.

In current U.S. prescribing information, treatment begins with a low dose and is gradually increased when appropriate. Dose escalation is designed in part to reduce gastrointestinal adverse reactions.

The appropriate dose should be determined by a healthcare professional rather than adjusted independently.

What Are the Common Side Effects?

Like other medications that affect incretin pathways, tirzepatide can cause gastrointestinal symptoms.

Common adverse reactions reported in U.S. prescribing information include:

• nausea
• diarrhea
• decreased appetite
• vomiting
• constipation
• dyspepsia
• abdominal pain

More serious warnings and precautions also exist, so treatment should be prescribed and monitored by an appropriate healthcare professional.

The Bottom Line

So, what is Mounjaro?

Mounjaro is a once-weekly injectable medication containing tirzepatide, a molecule that activates both GIP and GLP-1 receptors.

Its dual-receptor mechanism differentiates tirzepatide from medications that primarily target GLP-1 alone.

But another important distinction is regulatory.

Depending on the country, Mounjaro may be approved for type 2 diabetes, weight management, or both.

That is why discussions about tirzepatide should separate three different questions:

What molecule is being used?
Tirzepatide.

How does it work?
Through GIP and GLP-1 receptor activation.

What is it officially approved to treat?
That depends on the regulatory authority and country.

Understanding those differences is essential when comparing Mounjaro with other incretin-based treatments.